Use of andrographolide compounds for treating inflammation and airway disorders

An andrographolide, airway technology, applied in the direction of anhydride/acid/halide active ingredients, anti-inflammatory agents, drug combinations, etc., can solve problems such as shortness of breath and airflow limitation

Inactive Publication Date: 2012-05-30
NAT UNIV OF SINGAPORE
View PDF26 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This results in restricted airflow in and out of the lungs, causing shortness of breath

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of andrographolide compounds for treating inflammation and airway disorders
  • Use of andrographolide compounds for treating inflammation and airway disorders
  • Use of andrographolide compounds for treating inflammation and airway disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0095] We propose the use of andrographolide compounds such as andrographolide and DDA (DDAG) to supplement or replace oral steroids in airway disorders such as asthma exacerbations.

[0096] We describe a novel anti-inflammatory effect of andrographolide in asthma through inhibition of the nuclear factor-κB pathway. Sustained activation of nuclear factor (NF)-κB is associated with the development of asthma. Andrographolide, the main active ingredient of the medicinal plant Andrographis paniculata, was shown here to inhibit NF-κB activity. Andrographolide attenuates allergic asthma by inhibiting NF-κB signaling in BALB / c mice sensitized and stimulated with OVA, producing airway inflammation.

[0097] Andrographolide inhibited OVA-induced total cell count, eosinophil count, and levels of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid, and decreased serum levels of OVA-specific IgE. Andrographolide attenuates OVA-induced eosinophilia and airway mucus production in lung ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

We describe for the first time that andrographolide dirivatives such as DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-kappa B activity. Moreover, low dose of DDAG and glucocorticoid combination treatment synergistically attenuate inflammation in mouse asthma model. These findings support a therapeutic value for DDAG in the treatment of asthma.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of and priority to US Provisional Patent Application No. 61 / 162,861, filed March 24, 2009, the contents of which are hereby incorporated by reference. technical field [0003] The present application relates to compounds useful in the treatment of airway disorders such as asthma and chronic obstructive pulmonary disease. Background technique [0004] Airway disorders such as asthma and chronic obstructive pulmonary disease (COPD) afflict many people. Currently, approximately 300,000,000 people in the world suffer from asthma. The incidence is expected to rise to 400,000,000 in 2025. Asthma is a common chronic lung disease of the airways that is complex and characterized by variable and recurrent symptoms, airflow obstruction, bronchial hyperresponsiveness (bronchospasm) and underlying inflammation. The interplay of these features of asthma determines the clinical manifestations an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/19A61P11/06A61P11/08
CPCA61K31/365A61K31/19A61P11/00A61P11/06A61P11/08A61P29/00
Inventor 黄玮韶
Owner NAT UNIV OF SINGAPORE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap